RedHill Biopharma Ltd (RDHL)

[Spideyboy]

I like this line:

And another important distinguishing factor is the fact opaganib is oral. It’s easy to distribute and administer it. We can foresee its use in outpatient settings in mild cases of COVID-19 in the future and the more severe hospitalized cases. IV products are much harder to administer and distribute to patients outside of hospitals.

While the current trial is for moderate to severe Covid cases, I wholeheartedly agree that given its safety profile that opaganib can be used in the mild/moderate patients, before then even get to the moderate stage.

Again this drug appears to protect any cell that takes it up before the virus has encountered the cell, the logic is the sooner the better and good to see the first time the company has pro-actively mentioned it for earlier /lower disease severity. That expands the market drastically. Excellent